Animal Models of Obsessive–Compulsive Disorder: From Bench to Bedside via Endophenotypes and Biomarkers

Animal and Translational Models for CNS Drug Discovery

Volumn , Issue , 2008, Pages 133-164

  Joel, Daphna ^a   Stein, Dan J ^b   Schreiber, Rudy ^c  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884846765     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-373861-5.00006-0     Document Type: Chapter

References (184)

1. I.I. Gottesman and T.D. Gould (2003) The endophenotype concept in psychiatry: Etymology and strategic intentions. Am J Psychiat 160 636-645.
2. J.M. Hettema, M.C. Neale and K.S. Kendler (2001) A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychiat 158 1568-1578.
3. M.M. Weissman, R.C. Bland, G.J. Canino, S. Greenwald, H.-G. Hwu, C.K. Lee, et al. (1994) The cross national epidemiology of obsessive compulsive disorder. J Clin Psychiat 55S 5-10.
4. C.J.L. Murray and A.D. Lopez (1996) Global Burden of Disease: A Comprehensive Assessment of Mortality and Morbidity from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020. Havard: World Health Organisation
5. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders. 4th edition Washington, DC: American Psychiatric Press
6. C. Lochner and D.J. Stein (2003) Heterogeneity of obsessive–compulsive disorder: A literature review. Harv Rev Psychiat 11 113-132.
7. D. Mataix-Cols, M.C. Rosario-Campos M.C.d. and J.F. Leckman (2005) A multidimensional model of obsessive–compulsive disorder. Am J Psychiat 162 228-238.
8. D.J. Stein (2000) Neurobiology of the obsessive–compulsive spectrum disorders. Biologic Psychiat 47 296-304.
9. D.J. Stein (2002) Seminar on obsessive–compulsive disorder. Lancet 360 397-405.
10. S. Saxena, A.L. Brody, K.M. Maidment, E.C. Smith, N. Zohrabi, E. Katz, et al. (2004) Cerebral glucose metabolism in obsessive–compulsive hoarding. Am J Psychiat 161 1038-1048.
11. M.L. Phillips and D. Mataix-Cols (2004) Patterns of neural response to emotive stimuli distinguish the different symptom dimensions of obsessive–compulsive disorder. CNS Spectr 9 275-283.
12. C. Lochner, S.M.J. Hemmings, C.J. Kinnear, D.J.H. Niehaus, D.G. Nel, V.A. Corfield, et al. (2005) Cluster analysis of obsessive–compulsive spectrum disorders in patients with ­obsessive–­compulsive disorder: Clinical and genetic correlates. Compr Psychiat 46 14-19.
13. S.M.J. Hemmings, C.J. Kinnear, C. Lochner, D.J.H. Niehaus, J.A. Knowles, J.C. Moolman-Smook, et al. (2004) Early- versus late-onset obsessive–compulsive disorder: Investigating genetic and clinical correlates. Psychiat Res 128 175-182.
14. J.N. Giedd, J.L. Rapoport, M.A. Garvey, S. Perlmutter and S.E. Swedo (2000) MRI assessment of children with obsessive–compulsive disorder or tics associated with streptococcal infection. Am J Psychiat 157 281-283.
15. H.L. Leonard and S.E. Swedo (2001) Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS). Int J Neuropsychopharmacol 4 191-198.
16. L.A. Snider, L. Lougee, M. Slattery, P. Grant and S.E. Swedo (2005) Antibiotic prophylaxis with azithromycin or penicillin for childhood-onset neuropsychiatric disorders. Biologic Psychiat 57 788-792.
17. D.J. Stein, S.A. Montgomery, S. Kasper and P. Tanghoj (2001) Predictors of response to pharmacotherapy with citalopram in obsessive–compulsive disorder. Int Clin Psychopharmacol 16 357-361.
18. D. Denys and F. de Geus (2005) Predictors of pharmacotherapy response in anxiety disorders. Curr Psychiat Rep 7 252-257.
19. D.J. Stein and C. Lochner (2006) Obsessive–compulsive spectrum disorders: A multidimensional approach. Psychiatr Clin North Am 29 343-351.
20. D.L. Pauls, K.E. Towbin, J.F. Leckman, et al. (1986) Gilles de la Tourette’s syndrome and obsessive compulsive disorder: Evidence supporting a genetic relationship. Arch Gen Psychiat 43 1180-1182.
21. J. Moriarty, V. Eapen, D.C. Costa, S. Gacinovic, M. Trimble, P.J. Ell, et al. (1997) HMPAO SPET does not distinguish obsessive–compulsive and tic syndromes in families multiply affected with Gilles de la Tourette’s syndrome. Psychol Med 27 737-740.
22. D.J. Stein, Y. Liu, N.A. Shapira and W.K. Goodman (2001) The psychobiology of obsessive–compulsive disorder: how important is the role of disgust? Curr Psychiat Rep 3 281-287.
23. J.F. Abelson, K.Y. Kwan, B.J. O’Roak, D.Y. Baek, A.A. Stillman, T.M. Morgan, et al. (2005) Sequence variants in SLITRK1 are associated with Tourette’s syndrome. Science 310 317-320.
24. J.M. Greer and M.R. Capecchi (2002) Hoxb8 is required for normal grooming behavior in mice. Neuron 33 23-34.
25. J.S. Abramowitz (1997) Effectiveness of psychological and pharmacological treatments for obsessive–compulsive disorder: A quantitative review. J Consult Clin Psychol 65 44-52.
26. C.L. Barr, W.K. Goodman, L.H. Price, C.J. McDougle and D.S. Charney (1992) The serotonin hypothesis of obsessive compulsive disorder: implications of pharmacologic challenge studies. J Clin Psychiat 53S 17-28.
27. D.J. Stein, W.K. Goodman and S.L. Rauch (2000) The cognitive-affective neuroscience of obsessive–compulsive disorder. Curr Psychiat Rep 2 341-346.
28. N. Ozaki, D. Goldman, W.H. Kaye, K. Plotnicov, B.D. Greenberg, J. Lappalainen, et al. (2003) Serotonin transporter missense mutation associated with a complex neuropsychiatric phenotype. Mol Psychiat 8 933-936.
29. J.S. March, A. Frances, D. Carpenter and D. Kahn (1997) Treatment of obsessive–­compulsive disorder. The Expert Consensus Panel for obsessive–compulsive disorder. J Clin Psychiat 58S4 1-72.
30. B. Bandelow, J. Zohar, E. Hollander, S. Kasper and H.-J. Moller AWFSBP Task Force on Treatment Guidelines for Anxiety (2002) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive–compulsive and posttraumatic stress disorders. World J Biol Psychiat 3 171-199.
31. S. Pallanti, E. Hollander, C. Bienstock, L. Koran, J. Leckman, D. Marazziti, et al. (2002) Treatment non-response in OCD: methodological issues and operational definitions. Int Clin Psychopharmacol 5 181-191.
32. W.K. Goodman, C.J. McDougle and L.P. Lawrence (1990) Beyond the serotonin hypothesis: A role for dopamine in some forms of obsessive–compulsive disorder. J Clin Psychiat 51S 36-43.
33. C.J. McDougle, W.K. Goodman and J.F. Leckman (1994) Haloperidol addition in fluvoxamine-refractory obsessive–compulsive disorder: A double-blind placebo-controlled study in patients with and without tics. Arch Gen Psychiat 51 302-308.
34. Ipser, J.C., Carey, P., Dhansay, Y., Fakier, N., Seedat, S., and Stein, D.J. (2006). Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders, Cochrane Database Syst Rev CD005473.
35. D. Denys, J. Zohar and H.G.M. Westenberg (2004) The role of dopamine in obsessive–compulsive disorder: preclinical and clinical evidence. J Clin Psychiat 65 11-17.
36. D. Denys, N. van der Wee, J. Janssen, F. de Geus and H.G.M. Westenberg (2004) Low level of dopaminergic D2 receptor binding in obsessive–compulsive disorder. Biologic Psychiat 55 1041-1045.
37. N.J. van der Wee, H. Stevens, J.A. Hardeman, R.C. Mandl, D.A. Denys, H.J. van Megen, et al. (2004) Enhanced dopamine transporter density in psychotropic-naive patients with obsessive–compulsive disorder shown by [123I] beta-CIT SPECT. Am J Psychiat 161 2201-2206.
38. S.M. Stahl (2006) Finding what you are not looking for: strategies for developing novel treatments in psychiatry. NeuroRx 3 3-9.
39. M. El Mansari and P. Blier (2006) Mechanisms of action of current and potential pharmacotherapies of obsessive–compulsive disorder. Prog Neuropsychopharmacol Biol Psychiat 30 362-373.
40. P.L. Delgado and F.A. Moreno (1998) Hallucinogens, serotonin and obsessive–compulsive disorder. J Psychoactive Drug 30 359-366.
41. L.T. May, K. Leach, P.M. Sexton and A. Christopoulos (2007) Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 47 1-51.
42. S.K. Shenoy and R.J. Lefkowitz (2003) Trafficking patterns of beta-arrestin and G protein-coupled receptors determined by the kinetics of beta-arrestin deubiquitination. J Biol Chem 278 14498-14506.
43. A. Broocks, T.A. Pigott, J.L. Hill, S. Canter, T.A. Grady, F. L’Heureux and D.L. Murphy (1998) Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive–compulsive disorder (OCD): Behavioral and biological results. Psychiat Res 79 11-20.
44. R. Gross-Isseroff, R. Cohen, Y. Sasson, H. Voet and J. Zohar (2004) Serotonergic dissection of obsessive compulsive symptoms: A challenge study with m-chlorophenylpiperazine and sumatriptan. Neuropsychobiology 50 200-205.
45. E. Hollander, C. DeCaria, R. Gully, A. Nitescu, R.F. Suckow, J.M. Gorman, D.F. Klein and M.R. Liebowitz (1991) Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive–compulsive disorder. Psychiat Res 36 1-17.
46. D.L. Murphy, J. Zohar, C. Benkelfat, M.T. Pato, T.A. Pigott and T.R. Insel (1989) Obsessive–compulsive disorder as a 5-HT subsystem-related behavioural disorder. Br J Psychiat 5(Suppl), 15-24.
47. T.A. Pigott, J. Zohar, J.L. Hill, S.E. Bernstein, G.N. Grover, R.C. Zohar-Kadouch and D.L. Murphy (1991) Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive–compulsive disorder. Biol Psychiat 29 418-426.
48. T.A. Pigott, J.L. Hill, T.A. Grady, F. L’Heureux, S. Bernstein, C.S. Rubenstein and D.L. Murphy (1993) A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and the effect of metergoline prior to i.v. mCPP. Biol Psychiatry 33 3-14.
49. L. Stern, J. Zohar, R. Cohen and Y. Sasson (1998) Treatment of severe, drug resistant obsessive compulsive disorder with the 5HT1D agonist sumatriptan. Eur Neuropsychopharmacol 8 325-328.
50. J. Zohar, T.R. Insel, R.C. Zohar-Kadouch, J.L. Hill and D.L. Murphy (1988) Serotonergic responsivity in obsessive–compulsive disorder. Effects of chronic clomipramine treatment. Arch Gen Psychiat 45 167-172.
51. D.S. Charney, W.K. Goodman, L.H. Price, S.W. Woods, S.A. Rasmussen and G.R. Heninger (1988) Serotonin function in obsessive–compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects. Arch Gen Psychiat 45 177-185.
52. W.K. Goodman, C.J. McDougle, L.H. Price, L.C. Barr, O.F. Hills, J.F. Caplik, D.S. Charney and G.R. Heninger (1995) m-Chlorophenylpiperazine in patients with obsessive–compulsive disorder: absence of symptom exacerbation. Biol Psychiat 38 138-149.
53. K.L. Ho Pian, H.G. Westenberg, J.A. den Boer, W.I. de Bruin and P.P. van Rijk (2001) Effects of meta-chlorophenylpiperazine on cerebral blood flow in obsessive–compulsive disorder and controls. Biol Psychiat 44 367-370.
54. S. Khanna, J.P. John and L.P. Reddy (2001) Neuroendocrine and behavioral responses to mCPP in Obsessive–Compulsive Disorder. Psychoneuroendocrinology 26 209-223.
55. M. Yamauchi, T. Tatebayashi, K. Nagase, M. Kojima and T. Imanishi (2004) Chronic treatment with fluvoxamine desensitizes 5-HT2C receptor-mediated hypolocomotion in rats. Pharmacol Biochem Behav 78 683-689.
56. G.A. Kennett, S. Lightowler, V. de Biasi, N.C. Stevens, M.D. Wood, I.F. Tulloch and T.P. Blackburn (1994) Effect of chronic administration of selective 5-hydroxytryptamine and noradrenaline uptake inhibitors on a putative index of 5-HT2C/2B receptor function. Neuropharmacology 33 1581-1588.
57. D.J. Quested, P.A. Sargent and P.J. Cowen (1997) SSRI treatment decreases prolactin and hyperthermic responses to mCPP. Psychopharmacology (Berl) 133 305-308.
58. Flaisher-Grinberg, S., Klavir, O., and Joel, D. The role of 5-HT2a and 5-HT2c receptors in the signal attenuation rat model of obsessive compulsive disorder (submitted).
59. J.R. Martin, T.M. Ballard and G.A. Higgins (2002) Influence of the 5-HT2C receptor antagonist, SB-242084, in tests of anxiety. Pharmacol Biochem Behav 71 615-625.
60. W. Zhang, K.W. Perry, D.T. Wong, B.D. Potts, J. Bao, G.D. Tollefson and F.P. Bymaster (2000) Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 23 250-262.
61. A. Gobert, J.M. Rivet, F. Lejeune, A. Newman-Tancredi, A. Adhumeau-Auclair, J.P. Nicolas, L. Cistarelli, C. Melon and M.J. Millan (2000) Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic. but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat, Synapse 36 205-221.
62. H. Canton, L. Verriele and M.J. Millan (1994) Competitive antagonism of serotonin (5-HT)2C and 5-HT2A receptor-mediated phosphoinositide (PI) turnover by clozapine in the rat: A comparison to other antipsychotics. Neurosci Lett 181 65-68.
63. N.C. Vulink, D. Denys and H.G. Westenberg (2005) Bupropion for patients with obsessive–compulsive disorder: an open-label, fixed-dose study. J Clin Psychiat 66 228-230.
64. M.L. Carlsson, A. Carlsson and M. Nilsson (2004) Schizophrenia: from dopamine to glutamate and back. Curr Med Chem 11 267-277.
65. K.M. Connor, V.M. Payne, K.M. Gadde, W. Zhang and J.R. Davidson (2005) The use of aripiprazole in obsessive–compulsive disorder: preliminary observations in 8 patients. J Clin Psychiat 66 49-51.
66. C. Pittenger, J.H. Krystal and V. Coric (2006) Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive–compulsive disorder. NeuroRx 3 69-81.
67. W. Spooren, T. Ballard, F. Gasparini, M. Amalric, V. Mutel and R. Schreiber (2003) Insight into the function of Group I and Group II metabotropic glutamate (mGlu) receptors: behavioural characterization and implications for the treatment of CNS disorders. Behav Pharmacol 14 257-277.
68. V. Coric, S. Milanovic, S. Wasylink, P. Patel, R. Malison and J.H. Krystal (2003) Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive–compulsive disorder and major depressive disorder. Psychopharmacology (Berl) 167 219-220.
69. M.G. Kushner, S.W. Kim, C. Donahue, P. Thuras, D. Adson, M. Kotlyar, J. McCabe, J. Peterson and E.B. Foa (2007) D-cycloserine augmented exposure therapy for obsessive–compulsive disorder. Biol Psychiat 62 835-838.
70. E.A. Storch, L.J. Merlo, M. Bengtson, T.K. Murphy, M.H. Lewis, M.C. Yang, M.L. Jacob, M. Larson, A. Hirsh, M. Fernandez, G.R. Geffken and W.K. Goodman (2007) D-cycloserine does not enhance exposure-response prevention therapy in obsessive–compulsive disorder. Int Clin Psychopharmacol 22 230-237.
71. B.A. Fallon, M.R. Liebowitz, R. Campeas, F.R. Schneier, R. Marshall, S. Davies, et al. (1998) Intravenous clomipramine for obsessive–compulsive disorder refractory to oral clomipramine: A placebo-controlled study. Arch Gen Psychiat 55 918-924.
72. P.M. Salkovskis (1999) Understanding and treating obsessive–compulsive disorder. Behav Res Ther 37S1 29-52.
73. A. Nakagawa, I.M. Marks, J.M. Park, M. Bachofen, L. Baer, S.L. Dottl, et al. (2000) Self-­treatment of obsessive–compulsive disorder guided by manual and computer-conducted telephone interview. J Telemed Telecare 6 22-26.
74. A. Bystritsky, P.R. Munford, R.M. Rosen, et al. (1996) A preliminary study of partial hospital management of severe obsessive–compulsive disorder. Psychiat Serv 47 170-174.
75. B.D. Greenberg, L.H. Price, S.L. Rauch, G. Friehs, G. Noren, D. Malone, et al. (2003) Neurosurgery for intractable obsessive–compulsive disorder and depression: critical issues. Neurosur Clin North Am 14 199-212.
76. J.L. Abelson, G.C. Curtis, O. Sagher, R.C. Albucher, M. Harrigan, S.F. Taylor, et al. (2005) Deep brain stimulation for refractory obsessive–compulsive disorder. Biol Psychiatry 57 510-516.
77. P. Alonso, J. Pujol, N. Cardoner, L. Benlloch, J. Deus, J.M. Menchon, et al. (2001) Right prefrontal repetitive transcranial magnetic stimulation in obsessive–compulsive disorder: a double-blind, placebo-controlled study. Am J Psychiat 158 1143-1145.
78. S.P. Whiteside, J.D. Port and J.S. Abramowitz (2004) A meta-analysis of functional neuroimaging in obsessive–compulsive disorder. Psychiat Res 132 69-79.
79. L.R. Baxter, J.M. Schwartz, K.S. Bergman, et al. (1992) Caudate glucose metabolic rate changes with both drug and behavior therapy for OCD. Arch Gen Psychiat 49 681-689.
80. S. Saxena and K.M. Maidment (2004) Treatment of compulsive hoarding. J Clin Psychol 60 1143-1154.
81. M.A. Geyer and A. Markou (1995) Animal models of psychiatric disorders. F.E. Bloom, D.J. Kupfer (Eds) Psychopharmacology: The Fourth Generation of Progress New York: Raven Press Ltd 787-798.
82. M.A. Geyer and A. Markou (2002) The role of preclinical models in the development of psychotropic drugs. K.L. Davis, D. Charney, J.T. Coyle, C. Nemeroff (Eds) Neuropsychopharmacology: The Fifth Generation of Progress Lippincott Williams & Wilkins: Philadelphia 445-455.
83. S. Matthysse (1986) Animal models in psychiatric research. Prog Brain Res 65 259-270.
84. W.T. McKinney Jr. (1988) Models of mental disorders: A new comparative psychiatry. New York: Plenum Medical Book Co.
85. W.T. McKinney Jr. and W.E. Bunney Jr. (1969) Animal model of depression. I: Review of evidence: implications for research. Arch Gen Psychiat 21 240-248.
86. P. Willner (1984) The validity of animal models of depression. Psychopharmacology (Berl) 83 1-16.
87. P. Willner (1986) Validation criteria for animal models of human mental disorders: learned helplessness as a paradigm case. Prog Neuropsychopharmacol Biol Psychiat 10 677-690.
88. P. Willner (1991) Behavioural models in psychopharmacology. P. Willner (Eds) Behavioural Models in Psychopharmacology: Theoretical, Industrial and Clinical Perspectives Cambridge: Cambridge University Press 3-18.
89. D. Joel (2006) Current animal models of obsessive compulsive disorder: a critical review. Prog Neuropsychopharmacol Biol Psychiat 30 374-388.
90. S.V. Argyropoulos, J.J. Sandford and D.J. Nutt (2000) The psychobiology of anxiolytic drug, Part 2: Pharmacological treatments of anxiety. Pharmacol Ther 88 213-227.
91. M. Vaswani, F.K. Linda and S. Ramesh (2003) Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiat 27 85-102.
92. T.R. Insel, J. Mos and B. Olivier (1994) Animal models of obsessive compulsive disorder: A review. E. Hollander, J. Zohar, D. Marazzitti, B. Olivier (Eds) Current Insights in Obsessive Compulsive Disorder Chichester: John Wiley & Sons 117-135.
93. M. Bourin, A.J. Fiocco and F. Clenet (2001) How valuable are animal models in defining antidepressant activity? Hum Psychopharmacol 16 9-21.
94. O. Agid, S. Kapur, T. Arenovich and R.B. Zipursky (2003) Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiat 60 1228-1235.
95. P.S. Masand and S. Gupta (1999) Selective serotonin-reuptake inhibitors: an update. Harv Rev Psychiat 7 69-84.
96. S. Korff and B.H. Harvey (2006) Animal models of obsessive–compulsive disorder: rationale to understanding psychobiology and pharmacology. Psychiat Clin North Am 29 371-390.
97. J.T. Winslow and T.R. Insel (1991) Neuroethological models of obsessive–compulsive disorder. J. Zohar, T. Insel, S. Rasmussen (Eds) The Psychobiology of Obsessive–Compulsive Disorder New York: Springer Publishing Company 208-226.
98. D.J. Stein, N.H. Dodman, P. Borchelt and E. Hollander (1994) Behavioral disorders in veterinary practice: relevance to psychiatry. Compr Psychiat 35(4), 275-285.
99. J.N. Ricciardi and J. Hurley (1990) Development of animal models of obsessive–compulsive disorders. M.A. Jenike, L. Baer, W.E. Minichiello (Eds) Obsessive–Compulsive Disorders: Theory and Management 2nd edition Chicago: Year Book Medical Publishers, Inc 189-199.
100. R.K. Pitman (1991) Historical considerations. J. Zohar, T. Insel, S. Rasmussen (Eds) The Psychobiology of Obsessive–Compulsive Disorder New York: Springer Publishing Company 1-12.
101. A. Woods, C. Smith, M. Szewczak, R.W. Dunn, M. Cornfeldt and R. Corbett (1993) Selective serotonin re-uptake inhibitors decrease schedule-induced polydipsia in rats: a potential model for obsessive compulsive disorder. Psychopharmacology 112 195-198.
102. M. Altemus, J.R. Glowa, E. Galliven, Y.M. Leong and D.L. Murphy (1996) Effects of serotonergic agents on food-restriction-induced hyperactivity. Pharmacol Biochem Behav 53 123-131.
103. D. Joel (2006) The signal attenuation rat model of obsessive–compulsive disorder: a review. Psychopharmacology (Berl) 186 487-503.
104. S.R. Chamberlain, N.A. Fineberg, A.D. Blackwell, T.W. Robbins and B.J. Sahakian (2006) Motor inhibition and cognitive flexibility in obsessive–compulsive disorder and trichotillomania. Am J Psychiat 163 1282-1284.
105. S.B. Powell, H.A. Newman, J.F. Pendergast and M.H. Lewis (1999) A rodent model of spontaneous stereotypy: initial characterization of developmental, environmental, and neurobiological factors. Physiol Behav 66 355-363.
106. M.F. Presti and M.H. Lewis (2005) Striatal opioid peptide content in an animal model of spontaneous stereotypic behavior. Behav Brain Res 157 363-368.
107. M.F. Presti, H.M. Mikes and M.H. Lewis (2003) Selective blockade of spontaneous motor stereotypy via intrastriatal pharmacological manipulation. Pharmacol Biochem Behav 74 833-839.
108. S. Saxena, A.L. Brody, J.M. Schwartz and L.R. Baxter (1998) Neuroimaging and frontal-­subcortical circuitry in obsessive–compulsive disorder. Br J Psychiat Suppl 35 26-37.
109. Korff, S., Stein, D.J., and Harvey, B.H. Stereotypic behaviour in the deer mouse: Pharmaco­logical validation, relevance for obsessive compulsive disorder. Neuropsychopharmacology, Biol Psychiatry (in press).
110. I. Gyertyan (1995) Analysis of the marble burying response: marbles serve to measure digging rather than evoke burying. Behav Pharmacol 6 24-31.
111. T. Londei, A.M. Valentini and V.G. Leone (1998) Investigative burying by laboratory mice may involve non-functional, compulsive, behaviour. Behav Brain Res 94 249-254.
112. K. Njung’e and S.L. Handley (1991) Evaluation of marble-burying behavior as a model of anxiety. Pharmacol Biochem Behav 38 63-67.
113. C.L. Broekkamp, H.W. Rijk, D. Joly-Gelouin and K.L. Lloyd (1986) Major tranquillizers can be distinguished from minor tranquillizers on the basis of effects on marble burying and swim-induced grooming in mice. Eur J Pharmacol 126 223-229.
114. D. Treit (1985) The inhibitory effect of diazepam on defensive burying: anxiolytic vs. analgesic effects. Pharmacol Biochem Behav 22 47-52.
115. D. Treit, J.P. Pinel and H.C. Fibiger (1981) Conditioned defensive burying: a new paradigm for the study of anxiolytic agents. Pharmacol Biochem Behav 15 619-626.
116. C.L. Broekkamp and F. Jenck (1989) The relationship between various animal models of anxiety, fear-related psychiatric symptoms and response to serotonergic drugs. P. Bevan, R. Cools, T. Archer (Eds) Behavioural Pharmacology of 5-HT Hillsdale: Erlbaum 321-335.
117. H. Szechtman and E. Woody (2004) Obsessive–compulsive disorder as a disturbance of security motivation. Psychol Rev 111 111-127.
118. K. Hirano, R. Kimura, Y. Sugimoto, J. Yamada, S. Uchida, Y. Kato, H. Hashimoto and S. Yamada (2005) Relationship between brain serotonin transporter binding, plasma concentration and behavioural effect of selective serotonin reuptake inhibitors. Br J Pharmacol 144 695-702.
119. H. Takeuchi, S. Yatsugi and T. Yamaguchi (2002) Effect of YM992, a novel antidepressant with selective serotonin re-uptake inhibitory and 5-HT 2A receptor antagonistic activity, on a marble-burying behavior test as an obsessive–compulsive disorder model. Jpn J Pharmacol 90 197-200.
120. Y. Ichimaru, T. Egawa and A. Sawa (1995) 5-HT1A-receptor subtype mediates the effect of fluvoxamine, a selective serotonin reuptake inhibitor, on marble-burying behavior in mice. Jpn J Pharmacol 68 65-70.
121. D. Joel and A. Avisar (2001) Excessive lever pressing following post-training signal attenuation in rats: A possible animal model of obsessive compulsive disorder? Behav Brain Res 123 77-87.
122. D. Joel, A. Avisar and J. Doljansky (2001) Enhancement of excessive lever-pressing after post-training signal attenuation in rats by repeated administration of the D1 antagonist SCH 23390 or the D2 agonist quinpirole but not of the D1 agonist SKF 38393 or the D2 antagonist haloperidol. Behav Neurosci 115 1291-1300.
123. D. Joel, E. Ben-Amir, J. Doljansky and S. Flaisher (2004) ‘Compulsive’ lever-pressing in rats is attenuated by the serotonin re-uptake inhibitors paroxetine and fluvoxamine but not by the tricyclic antidepressant desipramine or the anxiolytic diazepam. Behav Pharmacol 15 241-252.
124. D. Joel and J. Doljansky (2003) Selective alleviation of ‘compulsive’ lever-pressing in rats by D1, but not D2, blockade: Possible implications for the involvement of D1 receptors in obsessive compulsive disorder. Neuropsychopharmacology 28 77-85.
125. D. Joel, J. Doljansky, N. Roz and M. Rehavi (2005) Role of the orbital cortex and the serotonergic system in a rat model of obsessive compulsive disorder. Neuroscience 130 25-36.
126. D. Joel, J. Doljansky and D. Schiller (2005) ‘Compulsive’ lever pressing in rats is enhanced following lesions to the orbital cortex, but not to the basolateral nucleus of the amygdala or to the dorsal medial prefrontal cortex. Eur J Neurosci 21 2252-2262.
127. L.R. Baxter (1999) Functional imaging of brain systems mediating obsessive–­compulsive disorder. C.E. Nestler W. Bunney (Eds) Neurobiology of Mental Illness New York: Oxford University Press 534-547.
128. G.F. Reed (1977) Obsessional personality disorder and remembering. Br J Psychiat 130 177-183.
129. M.W. Otto (1992) Normal and abnormal information processing: A neuropsychological perspective on obsessive–compulsive disorder. M.A. Jenike (Eds) The Psychiatric Clinics of North America. Obsessional Disorders Vol. 15 Chicago: W.B. Saunders Company, Harcourt Brace Jovanovich, Inc 825-848.
130. M. Graf (2006) 5-HT2c receptor activation induces grooming behaviour in rats: possible correlations with obsessive–compulsive disorder. Neuropsychopharmacol Hung 8 23-28.
131. S.L. Rauch and L.R. Baxter (1998) Neuroimaging in obsessive–compulsive and related disorders. M.A. Jenike, L. Baer, W.E. Minichiello (Eds) Obsessive–Compulsive Disorders: Practical Management 3rd Edition St. Louis, MO: Mosby 289-316.
132. E. Yadin, E. Friedman and W.H. Bridger (1991) Spontaneous alternation behavior: an animal model for obsessive–compulsive disorder? Pharmacol Biochem Behav 40 311-315.
133. D. Eilam and H. Szechtman (1995) Towards an animal model of obsessive–compulsive disorder (OCD): Sensitization to dopamine agonist quinpirole. Soc Neurosci Abstr 21 192.
134. H. Szechtman, W. Sulis and D. Eilam (1998) Quinpirole induces compulsive checking behavior in rats: a potential animal model of obsessive–compulsive disorder (OCD). Behav Neurosci 112 1475-1485.
135. H. Szechtman, M.J. Eckert, W.S. Tse, J.T. Boersma, C.A. Bonura, J.Z. McClelland, K.E. Culver and D. Eilam (2001) Compulsive checking behavior of quinpirole-sensitized rats as an animal model of Obsessive–Compulsive Disorder(OCD): form and control. BMC Neurosci 2 4.
136. A. Fernandez-Guasti, R.E. Ulloa and H. Nicolini (2003) Age differences in the sensitivity to clomipramine in an animal model of obsessive–compulsive disorder. Psychopharmacology (Berl) 166 195-201.
137. A. Ben-Pazi, H. Szechtman and D. Eilam (2001) The morphogenesis of motor rituals in rats treated chronically with the dopamine agonist quinpirole. Behav Neurosci 115 1301-1317.
138. D. Eilam and H. Szechtman (2005) Psychostimulant-induced behavior as an animal model of obsessive–compulsive disorder: An ethological approach to the form of compulsive rituals. CNS Spectr 10 1-12.
139. H. Szechtman and D. Eilam (2005) Psychiatric models. I.Q. Whishaw, B. Kolb (Eds) The Behavior of the Laboratory Rat: A Handbook with Tests London: Oxford University Press, Inc 462-474.
140. C. Winter, D. Joel, O. Klavir, A. Mundt, R. Jalali, S. Flash, J. Klein, D. Harnack, R. Morgenstern, G. Juckel and A. Kupsch (2007) Modulation of subthalamic Nucleus activity differentially affects compulsive behavior in rats. Pharmacopsychiatry 40 242.
141. A. Mundt, J. Klein, A. Heinz, R. Morgenstern, G. Juckel, A. Kupsch and C. Winter (2007) Deep brain stimulation of the Nucl. accumbens core and shell differentially reduces quinpirole-induced compulsive checking behavior in rats. Pharmacopsychiatry 40 246.
142. L. Mallet, V. Mesnage, J.L. Houeto, A. Pelissolo, J. Yelnik, C. Behar, M. Gargiulo, M.L. Welter, A.M. Bonnet, B. Pillon, P. Cornu, D. Dormont, B. Pidoux, J.F. Allilaire and Y. Agid (2002) Compulsions, Parkinson’s disease, and stimulation. Lancet 360 1302-1304.
143. D. Fontaine, V. Mattei, M. Borg, D. von Langsdorff, M.N. Magnie, S. Chanalet, P. Robert and P. Paquis (2004) Effect of subthalamic nucleus stimulation on obsessive–compulsive disorder in a patient with Parkinson disease. Case report. J Neurosurg 100 1084-1086.
144. B.D. Greenberg, D.A. Malone, G.M. Friehs, A.R. Rezai, C.S. Kubu, P.F. Malloy, S.P. Salloway, M.S. Okun, W.K. Goodman and S.A. Rasmussen (2006) Three-year outcomes in deep brain stimulation for highly resistant obsessive–compulsive disorder. Neuropsychopharmacology 31 2384-2393.
145. S.L. Rauch, D.D. Dougherty, D. Malone, A. Rezai, G. Friehs, A.J. Fischman, N.M. Alpert, S.N. Haber, P.H. Stypulkowski, M.T. Rise, S.A. Rasmussen and B.D. Greenberg (2006) A functional neuroimaging investigation of deep brain stimulation in patients with obsessive–compulsive disorder. J Neurosurg 104 558-565.
146. V. Sturm, D. Lenartz, A. Koulousakis, H. Treuer, K. Herholz, J.C. Klein and J. Klosterkotter (2003) The nucleus accumbens: a target for deep brain stimulation in obsessive–compulsive- and anxiety-disorders. J Chem Neuroanat 26 293-299.
147. K.M. Campbell, L. de Lecea, D.M. Severynse, M.G. Caron, M.J. McGrath, S.B. Sparber, L.Y. Sun and F.H. Burton (1999) OCD-Like behaviors caused by a neuropotentiating transgene targeted to cortical and limbic D1+ neurons. J Neurosci 19 5044-5053.
148. K.M. Campbell, M.J. McGrath and F.H. Burton (1999) Differential response of cortical-limbic neuropotentiated compulsive mice to dopamine D1 and D2 receptor antagonists. Eur J Pharmacol 371 103-111.
149. M.J. McGrath, K.M. Campbell, M.B. Veldman and F.H. Burton (1999) Anxiety in a transgenic mouse model of cortical-limbic neuro-potentiated compulsive behavior. Behav Pharmacol 10 435-443.
150. J.M. Welch, J. Lu, R.M. Rodriguiz, N.C. Trotta, J. Peca, J.D. Ding, C. Feliciano, M. Chen, J.P. Adams, J. Luo, S.M. Dudek, R.J. Weinberg, N. Calakos, W.C. Wetsel and G. Feng (2007) Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice. Nature 448 894-900.
151. J.M. Chou-Green, T.D. Holscher, M.F. Dallman and S.F. Akana (2003) Compulsive behavior in the 5-HT2C receptor knockout mouse. Physiol Behav 78 641-649.
152. K.C. Berridge, J.W. Aldridge, K.R. Houchard and X. Zhuang (2004) Sequential super-stereotypy of an instinctive fixed action pattern in hyper-dopaminergic mutant mice: a model of obsessive compulsive disorder and Tourette’s. BMC Biology 3 1-16.
153. K. Nonogaki, A.M. Strack, M.F. Dallman and L.H. Tecott (1998) Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene. Nat Med 4 1152-1156.
154. L.H. Tecott, L.M. Sun, S.F. Akana, A.M. Strack, D.H. Lowenstein, M.F. Dallman and D. Julius (1995) Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 374 542-546.
155. S.P. Vickers, P.G. Clifton, C.T. Dourish and L.H. Tecott (1999) Reduced satiating effect of d-fenfluramine in serotonin 5-HT(2C) receptor mutant mice. Psychopharmacology (Berl) 143 309-314.
156. B.A. Rocha, E.H. Goulding, L.E. O’Dell, A.N. Mead, N.G. Coufal and L.H. Parsons (2002) L.H. Tecott, Enhanced locomotor, reinforcing, and neurochemical effects of cocaine in serotonin 5-hydroxytryptamine 2C receptor mutant mice. J Neurosci 22 10039-10045.
157. L.H. Tecott, S.F. Logue, J.M. Wehner and J.A. Kauer (1998) Perturbed dentate gyrus function in serotonin 5-HT2C receptor mutant mice. Proc Natl Acad Sci USA 95 15026-15031.
158. S.R. Chamberlain, A.D. Blackwell, N.A. Fineberg, T.W. Robbins and B.J. Sahakian (2005) The neuropsychology of obsessive compulsive disorder: the importance of failures in cognitive and behavioural inhibition as candidate endophenotypic markers. Neurosci Biobehav Rev 29 399-419.
159. C.F. Gillespie and K.J. Ressler (2005) Emotional learning and glutamate: translational perspectives. CNS Spectr 10 831-839.
160. M. Davis, K. Ressler, B.O. Rothbaum and R. Richardson (2006) Effects of D-cycloserine on extinction: translation from preclinical to clinical work. Biol Psychiat 60 369-375.
161. M. Davis (2002) Role of NMDA receptors and MAP kinase in the amygdala in extinction of fear: clinical implications for exposure therapy. Eur J Neurosci 16 395-398.
162. K.J. Ressler, B.O. Rothbaum, L. Tannenbaum, P. Anderson, K. Graap, E. Zimand, L. Hodges and M. Davis (2004) Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiat 61 1136-1144.
163. M. Aigner, G. Sachs, E. Bruckmuller, B. Winklbaur, W. Zitterl, I. Kryspin-Exner, R. Gur and H. Katschnig (2007) Cognitive and emotion recognition deficits in obsessive–compulsive disorder. Psychiat Res 149 121-128.
164. N.A. Shapira, Y. Liu, A.G. He, M.M. Bradley, M.C. Lessig, G.A. James, D.J. Stein, P.J. Lang and W.K. Goodman (2003) Brain activation by disgust-inducing pictures in obsessive–compulsive disorder. Biol Psychiat 54 751-756.
165. A. Bertolino, G. Arciero, V. Rubino, V. Latorre, M. De Candia, V. Mazzola, G. Blasi, G. Caforio, A. Hariri, B. Kolachana, M. Nardini, D.R. Weinberger and T. Scarabino (2005) Variation of human amygdala response during threatening stimuli as a function of 5’HTTLPR genotype and personality style. Biol Psychiat 57 1517-1525.
166. A.R. Hariri, V.S. Mattay, A. Tessitore, et al. (2002) Serotonin transporter genetic variation and the response of the human amygdala. Science 297 400-403.
167. N.R. Swerdlow, C.H. Benbow, S. Zisook, M.A. Geyer and D.L. Braff (1993) A preliminary assessment of sensorimotor gating in patients with obsessive compulsive disorder. Biol Psychiat 33 298-301.
168. K. Hoenig, A. Hochrein, B.B. Quednow, W. Maier and M. Wagner (2005) Impaired prepulse inhibition of acoustic startle in obsessive–compulsive disorder. Biol Psychiat 57 1153-1158.
169. M. Yamashita, S. Fukushima, H.W. Shen, F.S. Hall, G.R. Uhl, Y. Numachi, H. Kobayashi and I. Sora (2006) Norepinephrine transporter blockade can normalize the prepulse inhibition deficits found in dopamine transporter knockout mice. Neuropsychopharmacology 31 2132-2139.
170. S.M. Hemmings, C.J. Kinnear, D.J. Niehaus, J.C. Moolman-Smook, C. Lochner, J.A. Knowles, V.A. Corfield and D.J. Stein (2003) Investigating the role of dopaminergic and serotonergic candidate genes in obsessive–compulsive disorder. Eur Neuropsychopharmacol 13 93-98.
171. A.M. Linden and D.D. Schoepp (2006) MGLUR targets for neuropsychiatric disorders. Drug Discov Today Therap Strategies 3 507-517.
172. L. Friedlander and M. Desrocher (2006) Neuroimaging studies of obsessive–compulsive disorder in adults and children. Clin Psychol Rev 26 32-49.
173. T. Nakao, A. Nakagawa, T. Yoshiura, E. Nakatani, M. Nabeyama, C. Yoshizato, A. Kudoh, K. Tada, K. Yoshioka, M. Kawamoto, O. Togao and S. Kanba (2005) Brain activation of patients with obsessive–compulsive disorder during neuropsychological and symptom provocation tasks before and after symptom improvement: a functional magnetic resonance imaging study. Biol Psychiat 57 901-910.
174. P.L. Remijnse, M.M. Nielen, A.J. van Balkom, D.C. Cath, P. van Oppen, H.B. Uylings and D.J. Veltman (2006) Reduced orbitofrontal-striatal activity on a reversal learning task in obsessive–compulsive disorder. Arch Gen Psychiat 63 1225-1236.
175. N.J. van der Wee, N.F. Ramsey, H.J. van Megen, D. Denys, H.G. Westenberg and R.S. Kahn (2007) Spatial working memory in obsessive–compulsive disorder improves with clinical response: A functional MRI study. Eur Neuropsychopharmacol 17 16-23.
176. M.M. Nielen and J.A. Den Boer (2003) Neuropsychological performance of OCD patients before and after treatment with fluoxetine: evidence for persistent cognitive deficits. Psychol Med 33 917-925.
177. K. McAlonan and V.J. Brown (2003) Orbital prefrontal cortex mediates reversal learning and not attentional set shifting in the rat. Behav Brain Res 146 97-103.
178. H.F. Clarke, S.C. Walker, J.W. Dalley, T.W. Robbins and A.C. Roberts (2007) Cognitive inflexibility after prefrontal serotonin depletion is behaviorally and neurochemically specific. Cereb Cortex 17 18-27.
179. Steckler, T. (2007). Preclinical biomarkers and surrogate markers in depression and anxiety. Proceedings of Translating Depression and Anxiety Therapeutics, MarcusEvans Conferences, 11 and 12 January 2007, London, UK.
180. J. Man, A.L. Hudson, D. Ashton and D.J. Nutt (2004) Animal models of obsessive compulsive disorder. Curr Neuropharmacol 2 1-7.
181. R.K. Pitman (1989) Animal models of compulsive behavior. Biol Psychiat 26(2), 189-198.
182. J.A. Gray (1982) The neuropsychology of anxiety: An enquiry into the functions of the septo-hippocampal system. New York: Oxford University Press
183. P. Malloy (1987) Frontal lobe dysfunction in obsessive compulsive disorder. E. Perecman (Eds) The Frontal Lobes Revisited New York: IRBN Press
184. R.K. Pitman (1987) A cybernetic model of obsessive–compulsive psychopathology. Compr Psychiat 28 334-343.